Tom H Johnston

List of Publications by Year
in descending order

59 papers	2,535 citations	156536 32 h-index	223390 49 g-index
59 all docs	59 docs citations	59 times ranked	2929 citing authors

#	Article	IF	Citations
1	Repurposing drugs to treat l-DOPA-induced dyskinesia in Parkinson's disease. Neuropharmacology, 2019, 147, 11-27.	2.0	26
2	Beneficial Effects of Trehalose on Striatal Dopaminergic Deficits in Rodent and Primate Models of Synucleinopathy in Parkinsonâ€™s Disease. Journal of Pharmacology and Experimental Therapeutics, 2019, 369, 364-374.	1.3	17
3	Pridopidine, a clinicâ€ready compound, reduces 3,4â€dihydroxyphenylalanineâ€induced dyskinesia in Parkinsonian macaques. Movement Disorders, 2019, 34, 708-716.	2.2	32
4	DPI-289, a novel mixed delta opioid agonist / mu opioid antagonist (DAMA), has L-DOPA-sparing potential in Parkinson's disease.. Neuropharmacology, 2018, 131, 116-127.	2.0	16
5	Pharmacokinetic/Pharmacodynamic Correlation Analysis of Amantadine for Levodopa-Induced Dyskinesia. Journal of Pharmacology and Experimental Therapeutics, 2018, 367, 373-381.	1.3	23
6	Towards a Non-Human Primate Model of Alpha-Synucleinopathy for Development of Therapeutics for Parkinsonâ€™s Disease: Optimization of AAV1/2 Delivery Parameters to Drive Sustained Expression of Alpha Synuclein and Dopaminergic Degeneration in Macaque. PLoS ONE, 2016, 11, e0167235.	1.1	42
7	Reproducibility of a Parkinsonism-related metabolic brain network in non-human primates: A descriptive pilot study with FDG PET. Movement Disorders, 2015, 30, 1283-1288.	2.2	18
8	Pioglitazone may impair <scp>Lâ€DOPA</scp> antiâ€parkinsonian efficacy in the <scp>MPTP</scp>â€lesioned macaque: Results of a pilot study. Synapse, 2015, 69, 99-102.	0.6	9
9	The highly-selective 5-HT1A agonist F15599 reduces l-DOPA-induced dyskinesia without compromising anti-parkinsonian benefits in the MPTP-lesioned macaque. Neuropharmacology, 2015, 97, 306-311.	2.0	39
10	L-745,870 reduces the expression of abnormal involuntary movements in the 6-OHDA-lesioned rat. Behavioural Pharmacology, 2015, 26, 101-108.	0.8	24
11	Primate Models of Complications Related to Parkinson Disease Treatment. , 2015, , 355-371.		0
12	The Opioid System in Levodopa-Induced Dyskinesia. , 2014, , 213-227.		0
13	UWA-121, a mixed dopamine and serotonin re-uptake inhibitor, enhances l-DOPA anti-parkinsonian action without worsening dyskinesia or psychosis-like behaviours in the MPTP-lesioned common marmoset. Neuropharmacology, 2014, 82, 76-87.	2.0	40
14	Symptomatic Models of Parkinsonâ€™s Disease and L-DOPA-Induced Dyskinesia in Non-human Primates. Current Topics in Behavioral Neurosciences, 2014, 22, 221-235.	0.8	22
15	RGFP109, a histone deacetylase inhibitor attenuates l-DOPA-induced dyskinesia in the MPTP-lesioned marmoset: A proof-of-concept study. Parkinsonism and Related Disorders, 2013, 19, 260-264.	1.1	21
16	The Pharmacology of l-DOPA-Induced Dyskinesia in Parkinsonâ€™s Disease. Pharmacological Reviews, 2013, 65, 171-222.	7.1	279
17	TC-8831, a nicotinic acetylcholine receptor agonist, reduces l-DOPA-induced dyskinesia in the MPTP macaque. Neuropharmacology, 2013, 73, 337-347.	2.0	38
18	Rotigotine polyoxazoline conjugate SERâ€214 provides robust and sustained antiparkinsonian benefit. Movement Disorders, 2013, 28, 1675-1682.	2.2	54

#	Article	IF	Citations
19	Use of catecholâ€<i>O</i>â€methyltransferase inhibition to minimize Lâ€3,4â€dihydroxyphenylalanineâ€induced dyskinesia in the 1â€methylâ€4â€phenylâ€1,2,3,6â€tetrahydropyridineâ€lesioned macaque. European Journal of Neuroscience, 2013, 37, 831-838.	1.2	5
20	Alternating Hemiplegia of Childhood-Related Neural and Behavioural Phenotypes in Na+,K+-ATPase Î±3 Missense Mutant Mice. PLoS ONE, 2013, 8, e60141.	1.1	39
21	L-745,870 Reduces l-DOPA-Induced Dyskinesia in the 1-Methyl-4-Phenyl-1,2,3,6-Tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2012, 342, 576-585.	1.3	39
22	A novel MDMA analogue, UWAâ€101, that lacks psychoactivity and cytotoxicity, enhances l â€DOPA benefit in parkinsonian primates. FASEB Journal, 2012, 26, 2154-2163.	0.2	22
23	The Monoamine Re-Uptake Inhibitor UWA-101 Improves Motor Fluctuations in the MPTP-Lesioned Common Marmoset. PLoS ONE, 2012, 7, e45587.	1.1	27
24	l-DOPA pharmacokinetics in the MPTP-lesioned macaque model of Parkinson's disease. Neuropharmacology, 2012, 63, 829-836.	2.0	37
25	5-HT2A receptor levels increase in MPTP-lesioned macaques treated chronically with L-DOPA. Neurobiology of Aging, 2012, 33, 194.e5-194.e15.	1.5	36
26	Regulation of cortical and striatal 5-HT1A receptors in the MPTP-lesioned macaque. Neurobiology of Aging, 2012, 33, 207.e9-207.e19.	1.5	34
27	A critique of available scales and presentation of the nonâ€human primate dyskinesia rating scale. Movement Disorders, 2012, 27, 1373-1378.	2.2	62
28	Increased levels of 5â€HT_{1A} receptor binding in ventral visual pathways in Parkinson's disease. Movement Disorders, 2012, 27, 735-742.	2.2	23
29	Progressive Neurodegeneration or Endogenous Compensation in an Animal Model of Parkinson's Disease Produced by Decreasing Doses of Alpha-Synuclein. PLoS ONE, 2011, 6, e17698.	1.1	82
30	Altered function of glutamatergic cortico-striatal synapses causes output pathway abnormalities in a chronic model of parkinsonism. Neurobiology of Disease, 2011, 41, 591-604.	2.1	31
31	The selective muâ€opioid receptor antagonist adl5510 reduces levodopaâ€induced dyskinesia without affecting antiparkinsonian action in mptpâ€lesioned macaque model of Parkinson's disease. Movement Disorders, 2011, 26, 1225-1233.	2.2	58
32	Generation of a model of l-DOPA-induced dyskinesia in two different mouse strains. Journal of Neuroscience Methods, 2011, 197, 193-208.	1.3	20
33	Experimental Models of l-DOPA-Induced Dyskinesia. International Review of Neurobiology, 2011, 98, 55-93.	0.9	4
34	Characterization of 3,4-Methylenedioxymethamphetamine (MDMA) Enantiomers<i>In Vitro</i>and in the MPTP-Lesioned Primate:<i>R</i>-MDMA Reduces Severity of Dyskinesia, Whereas<i>S</i>-MDMA Extends Duration of ON-Time. Journal of Neuroscience, 2011, 31, 7190-7198.	1.7	71
35	Fatty Acid Amide Hydrolase (FAAH) Inhibition Reduces l-3,4-Dihydroxyphenylalanine-Induced Hyperactivity in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Non-Human Primate Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2011, 336, 423-430.	1.3	35
36	Neuropsychiatric Behaviors in the MPTP Marmoset Model of Parkinsonâ€™s Disease. Canadian Journal of Neurological Sciences, 2010, 37, 86-95.	0.3	63

#	Article	IF	Citations
37	Effect of histamine H₂ receptor antagonism on levodopaâ€œinduced dyskinesia in the MPTPâ€macaque model of Parkinson's disease. Movement Disorders, 2010, 25, 1379-1390.	2.2	46
38	Increased 5â€HT_{2A} receptors in the temporal cortex of parkinsonian patients with visual hallucinations. Movement Disorders, 2010, 25, 1399-1408.	2.2	128
39	The Î±₂ adrenergic antagonist fipamezole improves quality of levodopa action in Parkinsonian primates. Movement Disorders, 2010, 25, 2084-2093.	2.2	35
40	Expression of human A53T alpha-synuclein in the rat substantia nigra using a novel AAV1/2 vector produces a rapidly evolving pathology with protein aggregation, dystrophic neurite architecture and nigrostriatal degeneration with potential to model the pathology of Parkinson's disease. Molecular Neurodegeneration, 2010, 5, 43.	4.4	106
41	Reduction of l-DOPA-Induced Dyskinesia by the Selective Metabotropic Glutamate Receptor 5 Antagonist 3-[(2-Methyl-1,3-thiazol-4-yl)ethynyl]pyridine in the 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaque Model of Parkinson's Disease. Journal of Pharmacology and Experimental Therapeutics, 2010, 333, 865-873.	1.3	130
42	Redesigning the designer drug ecstasy: non-psychoactive MDMA analogues exhibiting Burkitt's lymphoma cytotoxicity. MedChemComm, 2010, 1, 287.	3.5	11
43	Î±₁-Adrenoceptors Mediate Dihydroxyphenylalanine-Induced Activity in 1-Methyl-4-phenyl-1,2,3,6-tetrahydropyridine-Lesioned Macaques. Journal of Pharmacology and Experimental Therapeutics, 2009, 328, 276-283.	1.3	39
44	Dopamine D3 receptor stimulation underlies the development of L-DOPA-induced dyskinesia in animal models of Parkinson's disease. Neurobiology of Disease, 2009, 35, 184-192.	2.1	86
45	New insights into the organization of the basal ganglia. Current Neurology and Neuroscience Reports, 2009, 9, 298-304.	2.0	10
46	Receptorâ€activity modifying protein 1 expression is increased in the striatum following repeated <scp>L</scp>â€DOPA administration in a 6â€hydroxydopamine lesioned rat model of Parkinson's disease. Synapse, 2008, 62, 310-313.	0.6	8
47	The nociceptin/orphanin FQ (NOP) receptor antagonist Jâ€113397 enhances the effects of levodopa in the MPTPâ€lesioned nonhuman primate model of Parkinson's disease. Movement Disorders, 2008, 23, 1922-1925.	2.2	37
48	PYM50028, a novel, orally active, nonpeptide neurotrophic factor inducer, prevents and reverses neuronal damage induced by MPP ⁺ in mesencephalic neurons and by MPTP in a mouse model of Parkinson's disease. FASEB Journal, 2008, 22, 2488-2497.	0.2	74
49	Functional interaction between adenosine A2A and group III metabotropic glutamate receptors to reduce parkinsonian symptoms in rats. Neuropharmacology, 2008, 55, 483-490.	2.0	36
50	Histamine H3 receptor agonists reduce L-dopa-induced chorea, but not dystonia, in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders, 2006, 21, 839-846.	2.2	52
51	Pharmacological characterization of psychosis-like behavior in the MPTP-lesioned nonhuman primate model of Parkinson's disease. Movement Disorders, 2006, 21, 1879-1891.	2.2	97
52	Dopamine Receptor Agonists and Levodopa and Inducing Psychosis-Like Behavior in the MPTP Primate Model of Parkinson Disease. Archives of Neurology, 2006, 63, 1343.	4.9	51
53	Drugs in development for Parkinson's disease: an update. Current Opinion in Investigational Drugs, 2006, 7, 25-32.	2.3	15
54	Subcellular redistribution of the synapseâ€associated proteins PSDâ€95 and SAP97 in animal models of Parkinson&s disease and Lâ€DOPAâ€induced dyskinesia. FASEB Journal, 2005, 19, 1-25.	0.2	70

#	Article	IF	Citations
55	A simple rodent assay for the in vivo identification of agents with potential to reduce levodopa-induced dyskinesia in Parkinson's disease. Experimental Neurology, 2005, 191, 243-250.	2.0	27
56	Advances in the delivery of treatments for Parkinsonâ€™s disease. Expert Opinion on Drug Delivery, 2005, 2, 1059-1073.	2.4	32
57	Drugs in development for Parkinson's disease. Current Opinion in Investigational Drugs, 2004, 5, 720-6.	2.3	20
58	GABAB receptor agonists reverse akinesia following intranigral or intracerebroventricular injection in the reserpine-treated rat. British Journal of Pharmacology, 2003, 139, 1480-1486.	2.7	10
59	Changes in GABAB RECEPTOR mRNA expression in the rodent basal ganglia and thalamus following lesion of the nigrostriatal pathway. Neuroscience, 2003, 120, 1027-1035.	1.1	27